EA
ZYNE

Emerald Advisers’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Emerald Advisers’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-176,514
Closed -$2.3M – 322
2016
Q3 		$2.3M Hold
176,514
– – 0.1% 194
2016
Q2 		$1.21M Buy
176,514
+9,329
+6% +$78.1K 0.06% 228
2016
Q1 		$1.58M Sell
167,185
-69,885
-29% -$564K 0.08% 215
2015
Q4 		$2.39M Buy
237,070
+130,869
+123% +$1.73M 0.11% 191
2015
Q3 		$1.52M Buy
+106,201
New +$2.61M 0.08% 230

Other funds holding ZYNE

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $745M AUM 27.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Emerald Advisers's ZYNE Position: Q4 2016 in Review

Emerald Advisers sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2016, closing a stake of 176,514 shares — an estimated $2.3M sold.

Emerald Advisers first reported a position in ZYNE in Q3 2015 and held it in 5 quarters. The position peaked at $2.39M in Q4 2015. 34 funds tracked by Wall St. Rank hold ZYNE as of Q4 2016.

  • Emerald Advisers reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2016 after selling out during the quarter.
  • Emerald Advisers sold 176,514 Zynerba Pharmaceuticals, Inc shares in Q4 2016, an estimated $2.3M.
  • Emerald Advisers first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 5 quarters.
  • Emerald Advisers's Zynerba Pharmaceuticals, Inc position peaked at $2.39M in Q4 2015.
  • 34 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2016.

Based on Emerald Advisers's 13F filing for Q4 2016, filed 26 Jan 2017.